Determination of Caffeine and its Metabolites in Saliva and Urine as a Measure of CYP1A2 Metabolic Activity

被引:4
作者
Turjap, Miroslav [1 ,2 ]
Zendulka, Ondrej [1 ]
Glatz, Zdenek [3 ]
Brejcha, Stanislav [4 ]
Madr, Ales [3 ]
Jurica, Jan [1 ]
机构
[1] Masaryk Univ, Fac Med, Dept Pharm, Kamenice 5, Brno 62500, Czech Republic
[2] Univ Hosp Ostrava, Dept Clin Pharm, 17 Listopadu 1790, Ostrava 70852, Czech Republic
[3] Masaryk Univ, Fac Sci, Dept Biochem, Kamenice 5, Brno 62500, Czech Republic
[4] Masaryk Univ, Fac Med, Dept Biochem, Kamenice 5, Brno 62500, Czech Republic
关键词
Caffeine; CYP1A2; saliva; urine; phenotyping; metabolic ratio; PERFORMANCE LIQUID-CHROMATOGRAPHY; TANDEM MASS-SPECTROMETRY; IN-VIVO EVALUATION; XANTHINE-OXIDASE; EXTRACTIONLESS METHOD; RATIOS; 1A2; DRUG; METHYLXANTHINES; PHENOTYPE;
D O I
10.2174/1573412912666151119212608
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objective: The aim of this work was to develop a new, simple, rapid, sensitive and reproducible RP-HPLC method for the determination of caffeine, 1,7 dimethylxanthine, 1,7-dimethyluric acid, 5acetylamino- 6-formylamino-3-methyluracil, 5-acetylamino-6-amino-3-methyluracil, 1-methylxanthine, and 1-methyluric acid in human urine and saliva as a method of determining the metabolic activity of the human enzyme CYP1A2. Methods: A Luna C18(2) (150 x 4.6 mm i.d.) analytical column was used for the separation. The mobile phase consisted of sodium acetate trihydrate (pH 5.0) and methanol 85: 15 (v/v). The flow rate was maintained at 0.8 mL/min. The absorbance of the eluent was monitored at 263 nm (5-acetylamino-6-amino-3-methyluracil), 285 nm (5-acetylamino-6-formylamino-3-methyluracil, 1,7-dimethyluric acid, 1methyluric acid), 272 nm (caffeine, 1,7 dimethylxanthine) and 268 nm (1-methylxanthine). Acetaminophen as an internal standard was used to ensure the precision and accuracy of this method, and it was monitored at 245 nm. Results: All compounds, including the internal standard, were eluted within 18 min. Analytes were extracted by liquid-liquid extraction. Limits of quantitation varied from 7.2 to 74.2 mu g/L for individual analytes in saliva and from 8.4 to 82.4 mu g/L in urine. Conslusion: This method may become a useful alternative to urine caffeine metabolic ratio measurement with respect to CYP1A2 metabolic activity assessment in clinical practice.
引用
收藏
页码:325 / 332
页数:8
相关论文
共 34 条
[1]  
[Anonymous], 2001, Guidance for industry: bioanalytical method validation, P1
[2]   Development and validation of a rapid and efficient method for simultaneous determination of methylxanthines and their metabolites in urine using monolithic HPLC columns [J].
Atia, Noha N. ;
York, Peter ;
Clark, Brian J. .
JOURNAL OF SEPARATION SCIENCE, 2009, 32 (07) :931-938
[3]   In vivo evaluation of CYP1A2 CYP2A6, NAT-2 and xanthine oxidase activities in a Greek population sample by the RP-HPLC monitoring of caffeine metabolic ratios [J].
Begas, E. ;
Kouvaras, E. ;
Tsakalof, A. ;
Papakosta, S. ;
Asprodini, E. K. .
BIOMEDICAL CHROMATOGRAPHY, 2007, 21 (02) :190-200
[4]   Liquid chromatographic method for the simultaneous determination of caffeine and fourteen caffeine metabolites in urine [J].
Bendriss, EK ;
Markoglou, N ;
Wainer, IW .
JOURNAL OF CHROMATOGRAPHY B, 2000, 746 (02) :331-338
[5]   MONITORING CAFFEINE IN HUMAN SALIVA USING A NEWLY DEVELOPED ELISA [J].
Carvalho, Jose Joao ;
Weller, Michael G. ;
Panne, Ulrich ;
Schneider, Rudolf J. .
ANALYTICAL LETTERS, 2012, 45 (17) :2549-2561
[6]   Determination of urinary 13C-caffeine metabolites by liquid chromatography-mass spectrometry:: the use of metabolic ratios to assess CYP1A2 activity [J].
Caubet, MS ;
Comte, B ;
Brazier, JL .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2004, 34 (02) :379-389
[7]   Analysis of urinary caffeine metabolites by HPLC-DAD: the use of metabolic ratios to assess CYP1A2 enzyme activity [J].
Caubet, MS ;
Elbast, W ;
Dubuc, MC ;
Brazier, JL .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2002, 27 (1-2) :261-270
[8]  
de Araújo DM, 2014, CURR PHARM ANAL, V10, P231
[9]   Uncertainty factors for chemical risk assessment: human variability in the pharmacokinetics of CYP1A2 probe substrates [J].
Dorne, JLCM ;
Walton, K ;
Renwick, AG .
FOOD AND CHEMICAL TOXICOLOGY, 2001, 39 (07) :681-696
[10]   Assessment of CYP1A2 activity in clinical practice: Why, how, and when? [J].
Faber, MS ;
Jetter, A ;
Fuhr, U .
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2005, 97 (03) :125-134